Table 1.

Relationships of miRNA-1246 expression levels with clinicopathological characteristics and other key genes in NSCLC serum or FFPE tissues

Characteristics	No. of patients (%)	miRNA-1246 expression in serum		No. of patients (%)	miRNA-1246 expression in FFPE
		Mean (ΔCt)	p1		Low	High	p2
Age (year)
≤60	49 (43.8)	-1.17	0.170	40 (46.0)	18	22	0.830
>60	63 (56.2)	-1.98		47 (54.0)	23	24
Gender
Female	37 (33.0)	-2.41	0.061	23 (26.4)	12	11	0.631
Male	75 (67.0)	-1.24		64 (73.6)	29	35
Pathology3
SCC	56 (55.0)	-1.15	0.105	35 (40.2)	21	14	0.084
AC	56 (55.0)	-2.10		52 (59.8)	21	31
Differentiation
Well & Moderate	88 (78.6)	-1.43	0.213	67 (77.0)	29	38	0.446
Poor	24 (21.4)	-2.32		20 (23.0)	11	9
TNM stage
0~II	44 (39.3)	-2.307	0.062	31 (35.6)	18	13	0.826
III~IV	68 (60.7)	-1.187		56 (64.4)	31	25
Chemotherapy4
NP	42 (37.5)	-1.02	0.113	28 (32,2)	12	16	0.106
P or NP	70 (62.5)	-1.99		59 (67.8)	37	22
mTOR expression
Low	31 (35.6)	-0.66	0.047*	31 (35.6)	10	21	0.007**
High	56 (64.4)	-2.01		56 (64.4)	36	20
YY1 expression
Low	29 (33.3)	-2.57	0.022*	29 (33.3)	19	10	0.040*
High	58 (66.7)	-1.00		58 (66.7)	23	35
CDR1as expression
Low	45 (51.7)	-0.91	0.048*	45 (51.7)	13	35	0.005**
High	42 (48.3)	-2.19		42 (48.3)	24	18

¹Compared using Student t test;

²Compared using χ² test;

^*P<0.05;

^**P<0.01;

³SCC: squamous cell carcinoma, AC: adenocarcinoma;

⁴N: Non-platinum drugs; P: platinum drugs; NP: both non-platinum and platinum drugs.